Skip to content
Clinical Trials – home
Albireo AB
Sponsor

Albireo AB

Sweden S Annedal, Arvid Wallgrens Backe 20, Goteborgs Annedal, 413 46 Gothenburg, Sweden

About the sponsor

The sponsor concentrates on developing therapeutic interventions for rare cholestatic liver diseases affecting pediatric populations. Research efforts target conditions characterized by impaired bile flow and accumulation of toxic bile acids, which can lead to progressive liver damage in children. The organization's clinical programs address intrahepatic cholestasis and related hepatic complications that manifest during infancy and early childhood.

  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome
  • Biliary Atresia
  • Bile Acid Synthesis Disorders

The therapeutic approach focuses on modulating bile acid homeostasis and reducing the hepatotoxic effects of accumulated bile acids in pediatric patients with genetic and congenital liver disorders. Clinical investigations evaluate treatments designed to interrupt the enterohepatic circulation of bile acids, thereby alleviating pruritus and preventing progressive liver injury in children with these debilitating conditions.

About Specializations

Albireo AB runs clinical trials in conditions such as Cholangitis sclerosing, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

1 clinical trial

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).